Evaluates DIA LiP-MS workflows in proteomics, suggesting improved analysis for drug discovery.
Emerging as a powerful structural proteomics approach, limited proteolysis mass spectrometry (LiP-MS) has been widely employed to interrogate proteome-wide protein structural alterations, identify drug targets and drug-binding pockets, and probe protein–protein interactions. However, LiP-MS-based proteomics data analysis is fundamentally different from that of conventional proteomics informatics. LiP-MS relies on peptide-centric analysis in order to pinpoint structural regions or residues within a protein that exhibit conformational changes. The presence of a large number of semitryptic peptides substantially increases LiP-MS data complexity. Moreover, there is a lack of consensus on the statistical criteria for defining structural changes. To evaluate informatics workflows for DIA-based LiP-MS, we generated a high-quality benchmark data set comprising more than 170,000 LiP peptides with defined composition. We then performed a comprehensive assessment of major DIA analysis platforms incorporating different spectral libraries, and introduced DIA-LiPQuan, an informatics pipeline tailored to DIA LiP-MS quantification and downstream analysis. Data reanalysis by DIA-LiPQuan with in silico libraries allows sensitive and robust detection of both site-specific structural remodeling of proteins and drug-bound protein targets from the cellular proteome. Collectively, our study provides a valuable benchmark resource and informatics package for LiP-MS data mining, which would facilitate its broader applications in structural proteomics and drug discovery.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: